{"id":"https://openalex.org/W7225740778","doi":"https://doi.org/10.25251/rf9d0195","title":"Real-World Patient Experiences With Concomitant Ixekizumab and Tirzepatide in Psoriasis: Participants Recruited From the Zepbound\u00ae Savings for Taltz\u00ae US Customer Support Program","display_name":"Real-World Patient Experiences With Concomitant Ixekizumab and Tirzepatide in Psoriasis: Participants Recruited From the Zepbound\u00ae Savings for Taltz\u00ae US Customer Support Program","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225740778","doi":"https://doi.org/10.25251/rf9d0195"},"language":"en","primary_location":{"id":"doi:10.25251/rf9d0195","doi":"https://doi.org/10.25251/rf9d0195","is_oa":true,"landing_page_url":"https://doi.org/10.25251/rf9d0195","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/rf9d0195","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033903141","display_name":"April Wang Armstrong","orcid":"https://orcid.org/0000-0003-0064-8707","observed_orcids":["https://orcid.org/0000-0003-0064-8707"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"April Armstrong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008265068","display_name":"Ronald B. Prussick","orcid":"https://orcid.org/0000-0002-9375-2097","observed_orcids":["https://orcid.org/0000-0002-9375-2097"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ronald Prussick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081828039","display_name":"Adelaide Ann Hebert","orcid":"https://orcid.org/0000-0002-9167-5729","observed_orcids":["https://orcid.org/0000-0002-9167-5729"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adelaide A. Hebert","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000881645","display_name":"Susan G. Ball","orcid":"https://orcid.org/0000-0001-9866-6721","observed_orcids":["https://orcid.org/0000-0001-9866-6721"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Susan Ball","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048277820","display_name":"Ginger Haynes","orcid":"https://orcid.org/0000-0002-5664-162X","observed_orcids":["https://orcid.org/0000-0002-5664-162X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ginger Haynes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160777339","display_name":"Jill Zouzoulas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jill Zouzoulas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103278177","display_name":"Beth D. Mitchell","orcid":"https://orcid.org/0000-0002-0723-5393","observed_orcids":["https://orcid.org/0000-0002-0723-5393"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Beth Mitchell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066939573","display_name":"Miriam Kimel","orcid":"https://orcid.org/0000-0003-0783-8116","observed_orcids":["https://orcid.org/0000-0003-0783-8116"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Miriam Kimel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073312867","display_name":"Timothy A. Howell","orcid":"https://orcid.org/0000-0003-4110-540X","observed_orcids":["https://orcid.org/0000-0003-4110-540X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Timothy A. Howell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5091485944","display_name":"Bruce E Strober","orcid":"https://orcid.org/0000-0002-8394-2057","observed_orcids":["https://orcid.org/0000-0002-8394-2057"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruce Strober","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"s877","last_page":"s877"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C2779745271","wikidata":"https://www.wikidata.org/wiki/Q13574436","display_name":"Ixekizumab","level":5,"score":0.9002000093460083},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7671999931335449},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.7533000111579895},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.6165000200271606},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.5741999745368958},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.5645999908447266},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.5579000115394592},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.49050000309944153},{"id":"https://openalex.org/C2775944032","wikidata":"https://www.wikidata.org/wiki/Q22907659","display_name":"Patient satisfaction","level":2,"score":0.4343999922275543},{"id":"https://openalex.org/C2777929519","wikidata":"https://www.wikidata.org/wiki/Q7144988","display_name":"Patient education","level":2,"score":0.3440999984741211},{"id":"https://openalex.org/C2780221984","wikidata":"https://www.wikidata.org/wiki/Q131191","display_name":"Body mass index","level":2,"score":0.3418999910354614},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.328900009393692},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.320499986410141},{"id":"https://openalex.org/C2777501473","wikidata":"https://www.wikidata.org/wiki/Q1796666","display_name":"Body surface area","level":2,"score":0.31859999895095825},{"id":"https://openalex.org/C30036603","wikidata":"https://www.wikidata.org/wiki/Q17125150","display_name":"Severity of illness","level":2,"score":0.2874999940395355},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2689000070095062},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.25870001316070557},{"id":"https://openalex.org/C2777896191","wikidata":"https://www.wikidata.org/wiki/Q22907655","display_name":"Patient experience","level":3,"score":0.25679999589920044},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.2565999925136566}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/rf9d0195","doi":"https://doi.org/10.25251/rf9d0195","is_oa":true,"landing_page_url":"https://doi.org/10.25251/rf9d0195","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/rf9d0195","doi":"https://doi.org/10.25251/rf9d0195","is_oa":true,"landing_page_url":"https://doi.org/10.25251/rf9d0195","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":2,"referenced_works":["https://openalex.org/W7163131263","https://openalex.org/W7168337152"],"related_works":[],"abstract_inverted_index":{"Introduction:":[0],"Psoriasis":[1,167,177],"(PsO)":[2],"commonly":[3],"co-occurs":[4],"with":[5,36,45,50,76,98,261,270,426,437,444,472],"obesity/overweight":[6],"(OO)":[7],"and":[8,19,47,53,62,66,93,100,107,118,143,210,220,232,248,286,349,367,407,429,439,447,456,468,474],"shares":[9],"immunometabolic":[10],"pathways.":[11],"Ixekizumab":[12],"(IXE)":[13],"is":[14,22],"approved":[15],"to":[16],"treat":[17],"PsO,":[18],"tirzepatide":[20],"(TZP)":[21],"the":[23,39,123,159,233,275,278,463],"only":[24],"weight":[25,68,94,226,242,368,391,458],"loss":[26],"therapeutic":[27],"studied":[28],"in":[29,33,96,109,141,365],"a":[30,110,153,479],"controlled":[31],"trial":[32],"concomitant":[34,51,105,466],"use":[35],"IXE.":[37],"In":[38,132],"TOGETHER-PsO":[40],"trial,":[41],"significantly":[42],"more":[43],"participants":[44,74,97,260,397,423,436],"PsO":[46,99,117,192,262,298,311,438,473],"OO":[48,101,119,440,475],"treated":[49,75],"IXE":[52,77,106,135,219,283,428,446,467],"TZP":[54,108,144,221,290,371,378,469],"simultaneously":[55],"achieved":[56,399,404,410],"complete":[57],"skin":[58],"clearance":[59],"(Psoriasis":[60],"Area":[61],"Severity":[63],"Index":[64,202],"100)":[65],"\u226510%":[67],"reduction":[69,95,243,392],"at":[70],"36":[71],"weeks":[72],"than":[73],"alone.":[78],"The":[79,256],"current":[80,230,249],"observational":[81],"study":[82],"assessed":[83],"patient-reported":[84,161],"treatment":[85,434,481],"satisfaction,":[86],"disease":[87,319,351,451],"activity,":[88,452],"quality":[89],"of":[90,166,188,207,214,235,241,277,376,396,422,465,478],"life":[91],"(QoL),":[92],"who":[102,115],"were":[103,120,252,372],"taking":[104],"real-world":[111],"setting.":[112],"Methods:":[113],"Adults":[114],"had":[116,281,288,398,403,409,414],"recruited":[121],"from":[122,310],"US":[124],"customer":[125],"support":[126,462],"program,":[127],"Zepbound\u00ae":[128],"Savings":[129],"for":[130,191,218,291,470],"Taltz\u00ae.":[131],"this":[133],"cohort,":[134],"was":[136,145,244,379],"prescribed":[137,146,381],"by":[138,147,374,382],"healthcare":[139,149],"providers":[140,385],"dermatology":[142],"various":[148],"providers.":[150],"Participants":[151,223],"completed":[152],"cross-sectional":[154],"self-reported":[155],"survey,":[156,279],"which":[157],"included":[158,258],"following":[160],"outcomes:":[162],"Patient":[163,185,204,211],"Reported":[164],"Extent":[165],"Involvement":[168],"(PREPI,":[169],"including":[170],"percent":[171],"body":[172],"surface":[173],"area":[174],"[%BSA]),":[175],"Skinfold":[176],"Assessment":[178,187,213],"Form":[179],"(bother":[180],"Numeric":[181],"Rating":[182],"Scale":[183],"[NRS]),":[184],"Global":[186,205,212],"Disease":[189],"Activity":[190],"(PtGA-PsO),":[193],"Worst":[194],"Itch":[195,341],"NRS,":[196,198],"Fatigue":[197],"Dermatology":[199],"Life":[200],"Quality":[201],"(DLQI),":[203],"Impression":[206],"Change":[208],"(PGIC),":[209],"Treatment":[215],"Satisfaction":[216],"(PtGA-SAT;":[217],"separately).":[222],"reported":[224,373,424,441],"their":[225,229],"before":[227],"TZP,":[228,394,448],"weight,":[231],"number":[234],"pant":[236,417],"(trouser)":[237],"sizes":[238],"reduced.":[239],"Percentage":[240],"calculated":[245],"between":[246],"pre-TZP":[247],"weight.":[250],"Data":[251],"analyzed":[253],"descriptively.":[254],"Results:":[255],"survey":[257],"89":[259],"(82.0%":[263],"female;":[264],"mean":[265,300,322,332,343,356],"age,":[266],"46.3":[267],"years;":[268],"65.2%":[269,375],"psoriatic":[271],"arthritis":[272],"[PsA]).":[273],"At":[274],"time":[276],"76.4%":[280],"received":[282,289],"\u22656":[284,292],"months":[285],"47.2%":[287],"months.":[293],"Mean":[294],"scores":[295],"indicated":[296],"mild":[297,308,318,328,338],"(%BSA:":[299],"1.7;":[301],"standard":[302],"deviation":[303],"[SD]":[304],"5.4;":[305],"range":[306,316,326,336,347,360],"0.0\u201350.0),":[307],"bother":[309],"(mean":[312],"1.6;":[313],"SD":[314,324,334,345,358],"2.4;":[315],"0.0\u20139.0),":[317],"activity":[320],"(PtGA-PsO:":[321],"1.0;":[323],"1.3;":[325,344],"0.0\u20135.0),":[327],"fatigue":[329],"(Fatigue":[330],"NRS:":[331,342],"2.3;":[333,335],"0.0\u20138.0),":[337,348],"itch":[339],"(Worst":[340],"1.8;":[346],"minimal":[350],"impact":[352],"on":[353],"QoL":[354,454],"(DLQI:":[355],"2.6;":[357],"4.6;":[359],"0.0\u201326.0).":[361],"Patient-perceived":[362],"improvements":[363],"(PGIC)":[364],"PsO/PsA":[366],"since":[369,393],"starting":[370],"participants.":[377],"mostly":[380],"primary":[383],"care":[384],"(62.9%)":[386],"or":[387],"dermatologists":[388],"(21.3%).":[389],"Regarding":[390],"25.8%":[395],"0\u20135%":[400],"reduction,":[401,406],"13.5%":[402],">5\u201310%":[405],"60.7%":[408],">10%":[411],"reduction;":[412],"77.5%":[413],"experienced":[415],"\u22651":[416],"size":[418],"reduction.":[419,459],"Overall,":[420],"89.9%":[421],"satisfaction":[425,443],"both":[427,445],"TZP.":[430],"Conclusion:":[431],"Across":[432],"varying":[433],"durations,":[435],"high":[442],"alongside":[449],"low":[450,453],"burden,":[455],"substantial":[457],"These":[460],"findings":[461],"potential":[464],"patients":[471],"as":[476],"part":[477],"holistic":[480],"plan.":[482]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}